Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation

Abstract

Abstract Background Development of primary lung cancer in donor lung post-lung transplantation is very rare, with few described cases. The safety of stereotactic ablative radiotherapy (SABR) for early-stage lung cancer arising from donor lung is unclear. Case presentation Herein, we present a case of a patient with a Stage IB adenocarcinoma arising from donor lung 8 years post-double lung transplantation, which was performed due to advanced emphysema. The patient was ineligible for surgical management due to chronic lung allograft dysfunction, which significantly compromised pulmonary function. Full dose SABR was delivered with curative intent after a discussion with the patient. The patient tolerated the treatment well, with one episode of subacute toxicity that resolved with treatment. There was no evidence of recurrence at 15 months post-treatment and the patient’s pulmonary function did not deviate from the pre-SABR baseline. Conclusions SABR appears feasible for medically-inoperable early-stage primary lung adenocarcinoma in the setting of previous double-lung transplantation.

Keywords

• Stereotactic body radiotherapy
• Stereotactic ablative radiotherapy
• Early stage
• Non-small cell lung cancer
• Lung transplantation